Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00463021 · ClinicalTrials.gov registry record · Phase 4
A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection
A Phase 4 study, sponsored by Genzyme, a Sanofi Company.
- Completed
- Registry status
- Phase 4
- Development phase
- 36
- Enrollment target
NCT00463021 is a Phase 4 study that has completed, run by Genzyme, a Sanofi Company. The registered enrollment target is 36 participants.
The verdict
NCT00463021, a Phase 4 study, has completed, sponsored by Genzyme, a Sanofi Company.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 36 participants
- Enrollment target
Study Summary
Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.
Interventions
- DRUG Hectorol (doxercalciferol capsules)
- DRUG Zemplar (paricalcitol injection)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 36 participants |
| Start Date | 2007-04 |
| Est. Completion | 2007-12 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00463021
The ClinicalTrials.gov registry entry for NCT00463021 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 36 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Genzyme, a Sanofi Company, which has 196 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Hectorol (doxercalciferol capsules) is the first listed.
NCT00463021 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00463021 about?
NCT00463021 is a clinical study titled "A Phase 4 Study to Determine Dosing of Hectorol® Capsules When Converting From Zemplar® Injection". Protocol HECT00306 aims to determine clinically appropriate doses of Hectorol (doxercalciferol capsules) when converting from Zemplar (paricalcitol injection) for the treatment of secondary hyperparathyroidism in Stage 5 chronic kidney disease on hemodialysis.
What is the current status of trial NCT00463021?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 36 participants. The study started on 2007-04. Estimated completion is 2007-12.
What interventions are being tested in trial NCT00463021?
The interventions under investigation include: Hectorol (doxercalciferol capsules) (DRUG), Zemplar (paricalcitol injection) (DRUG).
Who is sponsoring clinical trial NCT00463021?
This trial is sponsored by Genzyme, a Sanofi Company, which has 196 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.